×
About 1,288 results

ALLMedicine™ Paroxysmal Nocturnal Hemoglobinuria Center

Research & Reviews  424 results

Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
https://clinicaltrials.gov/ct2/show/NCT00003838

May 20th, 2022 - Patients with malignant and non-malignant hematologic diseases including severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome (MDS), acute and chronic leukemias, Hodgkin's and non-Hodgkin's lymphoma and...

Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort ...
https://doi.org/10.1182/bloodadvances.2022006960
Blood Advances; Jang JH, Wong Lee Lee L et. al.

May 14th, 2022 - Iptacopan (LNP023) is a novel, oral selective inhibitor of complement factor B under clinical development for paroxysmal nocturnal hemoglobinuria (PNH). In this ongoing open-label phase 2 study, PNH patients with active hemolysis were randomized t...

A Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors.
https://clinicaltrials.gov/ct2/show/NCT04432584

May 12th, 2022 - A study designed to evaluate the non-inferiority of crovalimab compared with eculizumab in participants with PNH currently treated with complement inhibitors. This study will enroll approximately 250 participants.

Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
https://clinicaltrials.gov/ct2/show/NCT04747613

May 12th, 2022 - The purpose of this phase 3 open-label, single arm, multicenter study is to evaluate the long-term safety, tolerability and efficacy of iptacopan in patients with PNH and to provide access to patients who have completed (without tapering down) Pha...

A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria
https://clinicaltrials.gov/ct2/show/NCT03406507

May 9th, 2022 - The study consists of a 4-week Screening Period, a 26-week Primary Evaluation Period, and an Extension Period of up to 4 years (with the exception of any country-specific mandates), whichever occurs first. Efficacy and safety data are reported for...

see more →

Guidelines  1 results

Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and ...
https://doi.org/10.1002/cyto.b.20525
Cytometry. Part B, Clinical Cytometry; Borowitz MJ, Craig FE et. al.

Jun 10th, 2010 - Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematopoietic stem cell disorder characterized by a somatic mutation in the PIGA gene, leading to a deficiency of proteins linked to the cell membrane via glycophosphatidylinositol (GPI) anchors....

see more →

Drugs  6 results see all →

Clinicaltrials.gov  30 results

Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
https://clinicaltrials.gov/ct2/show/NCT00003838

May 20th, 2022 - Patients with malignant and non-malignant hematologic diseases including severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome (MDS), acute and chronic leukemias, Hodgkin's and non-Hodgkin's lymphoma and...

Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
https://clinicaltrials.gov/ct2/show/NCT04747613

May 12th, 2022 - The purpose of this phase 3 open-label, single arm, multicenter study is to evaluate the long-term safety, tolerability and efficacy of iptacopan in patients with PNH and to provide access to patients who have completed (without tapering down) Pha...

A Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors.
https://clinicaltrials.gov/ct2/show/NCT04432584

May 12th, 2022 - A study designed to evaluate the non-inferiority of crovalimab compared with eculizumab in participants with PNH currently treated with complement inhibitors. This study will enroll approximately 250 participants.

A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria
https://clinicaltrials.gov/ct2/show/NCT03406507

May 9th, 2022 - The study consists of a 4-week Screening Period, a 26-week Primary Evaluation Period, and an Extension Period of up to 4 years (with the exception of any country-specific mandates), whichever occurs first. Efficacy and safety data are reported for...

Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study
https://clinicaltrials.gov/ct2/show/NCT03225287

Apr 19th, 2022 - The purpose of this study is to enable continued access to zilucoplan (RA101495) for patients with paroxysmal nocturnal hemoglobinuria (PNH) after they complete a zilucoplan clinical study.

see more →

News  52 results

Pegcetacoplan Improves Efficacy in Complement Inhibitor–Naïve Paroxysmal Nocturnal Hemoglobinuria
https://www.onclive.com/view/pegcetacoplan-improves-efficacy-in-complement-inhibitor-na-ve-paroxysmal-nocturnal-hemoglobinuria

Apr 9th, 2022 - Pegcetacoplan (Empaveli) treatment was associated with hemoglobin stabilization and normalization, as well as a superior change from baseline in hemoglobin levels, which showed a meaningful correction of anemia, in patients with complement inhibit...

Phase 3 Drug Trial for ALS Halted for Lack of Efficacy
https://www.medscape.com/viewarticle/957004

Aug 20th, 2021 - A global phase 3 trial of ravulizumab (Ultomiris) for adults with amyotrophic lateral sclerosis (ALS) is being discontinued following a data review, its manufacturer has announced. The CHAMPION-ALS placebo-controlled trial had enrolled 382 adults ...

FDA Approves New Treatment Option for Rare Anemia
https://www.medscape.com/viewarticle/951476

May 19th, 2021 - A rare, life-threatening anemia now has a new treatment option. The Food and Drug Administration announced the approval of pegcetacoplan (Empaveli) injection to treat adults with paroxysmal nocturnal hemoglobinuria (PNH). Pegcetacoplan is the firs...

VEXAS Syndrome: Implications for Dermatologists
https://www.medscape.com/viewarticle/949785

Apr 22nd, 2021 - When I was a medical student, I always found it gratifying when there was a unifying mechanism that explained the symptoms of a disease. Part of the reason I chose dermatology as a specialty was how frequently we are able to "see" these mechanisms...

Diagnostic Challenges: When Is It MDS
https://www.onclive.com/view/diagnostic-challenges-when-is-it-mds

Apr 2nd, 2021 - Transcript:Mikkael A. Sekeres, MD, MS: You’re getting at a little bit to what Rami referred to earlier as the clonal hematopoiesis of indeterminate potential, people who have these clonal abnormalities and may not have overt blood abnormalities or...

see more →

Patient Education  2 results see all →